Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A SARM1-mitochondrial feedback loop drives neuropathogenesis in a Charcot-Marie-Tooth disease type 2A rat model
Yurie Sato-Yamada, … , Aaron DiAntonio, Jeffrey Milbrandt
Yurie Sato-Yamada, … , Aaron DiAntonio, Jeffrey Milbrandt
Published October 26, 2022
Citation Information: J Clin Invest. 2022;132(23):e161566. https://doi.org/10.1172/JCI161566.
View: Text | PDF
Research Article Neuroscience

A SARM1-mitochondrial feedback loop drives neuropathogenesis in a Charcot-Marie-Tooth disease type 2A rat model

  • Text
  • PDF
Abstract

Charcot-Marie-Tooth disease type 2A (CMT2A) is an axonal neuropathy caused by mutations in the mitofusin 2 (MFN2) gene. MFN2 mutations result in profound mitochondrial abnormalities, but the mechanism underlying the axonal pathology is unknown. Sterile α and Toll/IL-1 receptor motif–containing 1 (SARM1), the central executioner of axon degeneration, can induce neuropathy and is activated by dysfunctional mitochondria. We tested the role of SARM1 in a rat model carrying a dominant CMT2A mutation (Mfn2H361Y) that exhibits progressive dying-back axonal degeneration, neuromuscular junction (NMJ) abnormalities, muscle atrophy, and mitochondrial abnormalities — all hallmarks of the human disease. We generated Sarm1-KO (Sarm1–/–) and Mfn2H361Y Sarm1 double-mutant rats and found that deletion of Sarm1 rescued axonal, synaptic, muscle, and functional phenotypes, demonstrating that SARM1 was responsible for much of the neuropathology in this model. Despite the presence of mutant MFN2 protein in these double-mutant rats, loss of SARM1 also dramatically suppressed many mitochondrial defects, including the number, size, and cristae density defects of synaptic mitochondria. This surprising finding indicates that dysfunctional mitochondria activated SARM1 and that activated SARM1 fed back on mitochondria to exacerbate the mitochondrial pathology. As such, this work identifies SARM1 inhibition as a therapeutic candidate for the treatment of CMT2A and other neurodegenerative diseases with prominent mitochondrial pathology.

Authors

Yurie Sato-Yamada, Amy Strickland, Yo Sasaki, Joseph Bloom, Aaron DiAntonio, Jeffrey Milbrandt

×

Figure 1

The Mfn2H361Y mutation causes progressive neurodegeneration and muscle wasting.

Options: View larger image (or click on image) Download as PowerPoint
The Mfn2H361Y mutation causes progressive neurodegeneration and muscle w...
(A) Toluidine blue–stained cross sections of sciatic nerves from WT and Mfn2H361Y/+ rats at 6 and 12 months of age. (B) Distribution of axonal diameters of distal sciatic nerves in WT and Mfn2H361Y/+ rats at 6 and 12 months of age (n = 3). *P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. (C) STMN2 in tibial nerves of WT and Mfn2H361Y/+ rats at 6 and 12 months of age. Graph shows the percentage of the STMN2 immunopositive area per mm2 for each genotype and age (n = 3–5). ****P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. Original magnification, ×100. (D) Representative images of NMJs in WT and Mfn2H361Y/+ rats at 6 and 12 months of age, stained in green to detect the marker synaptic vesicle glycoprotein 2A (SV2A) and the axon marker neurofilament medium chain (NEFM) and in red with the postsynaptic endplate marker bungarotoxin. The upper graph exhibits terminal axon diameters and the lower graph exhibits endplate volumes in WT and Mfn2H361Y/+ rats at 6 and 12 months of age (n = 3–4). ****P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. Scale bar: 20 μm. (E) Cross sections of H&E-stained lumbrical muscles from WT and Mfn2H361Y/+ rats at 6 and 12 months of age. Scale bar: 50 μm. (F) Representative image of group atrophy (encircled by dotted line) in 12-month-old Mfn2H361Y/+ rat muscle stained with H&E. Scale bar: 50 μm. (G) Cross sections of gastrocnemius muscle from 12-month-old WT and Mfn2H361Y/+ rats; tissues were immunostained for myosin heavy chain (MHC) type IIA (SC-71) and BF-F3 MHC type IIB to highlight altered fiber type distribution in the mutant animals. Scale bar: 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts